Literature DB >> 10873660

Promoter analysis and chromosomal mapping of human EBAG9 gene.

K Ikeda1, M Sato, O Tsutsumi, F Tsuchiya, M Tsuneizumi, M Emi, I Imoto, J Inazawa, M Muramatsu, S Inoue.   

Abstract

The human EBAG9 was previously identified as an estrogen responsive gene using CpG-genomic binding site cloning (Watanate et al., (1998) Mol. Cell. Biol. 18: 442-449). Recently it was revealed that the EBAG9 is identical with RCAS1 which is a cancer cell surface antigen implicated in immune escape. Here, we isolated and analyzed the 5'-flanking region of human EBAG9 gene. We determined transcription initiation site, which has a homology with an initiator element YYCAYYYY, and found that TATA motif was absent. Deletion analysis of the 5'-flanking region using MCF-7 breast cancer cells indicated that the sequences -86 to -36 containing the ERE had the basal level of promoter activity and the upstream GC-rich region positively regulated the activity. EBAG9 promoter luciferase reporters containing the ERE could respond to estrogen, and electrophoretic mobility shift assay showed that ERalpha bound to the ERE. Moreover, fluorescent in situ hybridization analysis has shown that the human EBAG9 gene is located at chromosome 8q23 which is frequently amplified in tumors. These findings suggest that the human EBAG9 might be involved in carcinogenesis as an estrogen responsive gene. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873660     DOI: 10.1006/bbrc.2000.2920

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  EBAG9 adds a new layer of control on large dense-core vesicle exocytosis via interaction with Snapin.

Authors:  Constantin Rüder; Tatiana Reimer; Ignacio Delgado-Martinez; Ricardo Hermosilla; Arne Engelsberg; Ralf Nehring; Bernd Dörken; Armin Rehm
Journal:  Mol Biol Cell       Date:  2005-01-05       Impact factor: 4.138

2.  Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.

Authors:  Tatiana A Reimer; Ioannis Anagnostopoulos; Bettina Erdmann; Insa Lehmann; Harald Stein; Peter Daniel; Bernd Dörken; Armin Rehm
Journal:  BMC Cancer       Date:  2005-05-17       Impact factor: 4.430

3.  EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions.

Authors:  T Suzuki; S Inoue; W Kawabata; J Akahira; T Moriya; F Tsuchiya; S Ogawa; M Muramatsu; H Sasano
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

4.  In silico selection of an aptamer to estrogen receptor alpha using computational docking employing estrogen response elements as aptamer-alike molecules.

Authors:  Rajesh Ahirwar; Smita Nahar; Shikha Aggarwal; Srinivasan Ramachandran; Souvik Maiti; Pradip Nahar
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

5.  The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse.

Authors:  Magdalena Dutsch-Wicherek; Romana Tomaszewska; Agata Lazar; Lukasz Wicherek; Jacek Skladzien
Journal:  BMC Cancer       Date:  2009-01-28       Impact factor: 4.430

6.  Association between RCAS1 expression and clinical outcome in uterine endometrial cancer.

Authors:  K Sonoda; S Miyamoto; T Hirakawa; T Kaku; M Nakashima; T Watanabe; K Akazawa; T Fujita; H Nakano
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

7.  Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.

Authors:  J-I Akahira; M Aoki; T Suzuki; T Moriya; H Niikura; K Ito; S Inoue; K Okamura; H Sasano; N Yaegashi
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.